ceftaroline fosamil (Zinforo)

Following a full submission:

ceftaroline fosamil (Zinforo) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of complicated skin and soft tissue infections in adults.

SMC restriction: use in patients with known or suspected meticillin resistant Staphylococcus aureus (MRSA) infection in the following settings:

For Gram-positive only infections where vancomycin iv is inappropriate/has not been tolerated or treatment modification is required; and daptomycin iv or linezolid iv is normally used.

For polymicrobial Gram-positive and common Gram-negative pathogens*, where vancomycin iv in combination with gentamicin iv is inappropriate/has not been tolerated or treatment modification is required; and daptomycin iv in combination with gentamicin iv, or linezolid iv in combination with gentamicin iv, or tigecycline iv is normally used.

Ceftaroline should be used only on the advice of local microbiologists or specialists in infectious disease.

In two randomised, controlled clinical studies, intravenous ceftaroline fosamil was non-inferior to intravenous vancomycin plus aztreonam in adult patients with complicated skin and skin structure infections.

Ceftaroline is also licensed for the treatment of community acquired pneumonia. As the company submission related only to the treatment of skin and soft tissue infections, SMC cannot recommend the use of ceftaroline in community acquired pneumonia.